Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Rohrer

MOHS-Micrographic Surgery Chestnut Hill, MA Medical Doctor

NPI 1053384693 CMS profile 183535

1244 Boylston St, Suite 302, Chestnut Hill, MA 02467

Open in the dashboard

General payments

$9,021

369 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$33,675 paid to institutions, not to them · program year 2019

Through program year 2025, Thomas Rohrer of Chestnut Hill, MA is reported in the CMS Open Payments database as having received $9,021 across 369 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $33,675 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,525 60
2024 General $1,871 67
2023 General $1,468 59
2022 General $1,201 47
2021 General $1,230 60
2020 General $688 27
2019 General $1,037 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Rohrer
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Thomas Rohrer were reported at $1,525. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Thomas Rohrer MOHS-Micrographic Surgery median Middle half National median
2019 $1,037 $316 $106–$785 $163
2020 $688 $162 $68–$412 $114
2021 $1,230 $243 $87–$654 $132
2022 $1,201 $300 $102–$887 $149
2023 $1,468 $364 $125–$1,010 $160
2024 $1,871 $445 $142–$1,108 $164
2025 $1,525 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,720 63 payments
  2. UCB, Inc. $770 31 payments
  3. Sun Pharmaceutical Industries Inc. $747 34 payments
  4. Lilly USA, LLC $614 27 payments
  5. Amgen Inc. $554 21 payments
  6. Janssen Biotech, Inc. $534 24 payments
  7. Novartis Pharmaceuticals Corporation $519 21 payments
  8. Galderma Laboratories, L.P. $489 21 payments
  9. Incyte Corporation $473 20 payments
  10. LEO Pharma Inc. $466 20 payments
  11. Other $2,135 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,021 369 payments
Products named General payments · program years 2019–2025
  1. TALTZ $614 27 payments
  2. SKYRIZI $580 26 payments
  3. OPZELURA $473 20 payments
  4. TREMFYA $463 20 payments
  5. HUMIRA $458 22 payments
  6. Cimzia $456 18 payments
  7. Otezla $454 17 payments
  8. BOTOX $413 2 payments
  9. Winlevi $412 15 payments
  10. ILUMYA $334 19 payments
  11. Other $5,112 236 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

295

Median for Dermatology: 534

Drug cost

$7,371

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 82 $1,315
Fluorouracil Generic 22 $1,208
Imiquimod Generic 14 $1,200
Calcipotriene Generic 12 $1,131
Ketoconazole Generic 20 $800
Clobetasol Propionate Generic 18 $793
Cephalexin Generic 78 $397
Triamcinolone Acetonide Generic 24 $343
Mupirocin Generic 25 $185

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$814,827

Of which drugs: $2,415

Medicare patients

836

Average age 78

Services billed

3,999

391 women, 445 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 44%
Ischemic heart disease 24%
Chronic kidney disease 20%
Osteoporosis 20%
Atrial fibrillation 19%
Cancer 19%
Diabetes 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fluorouracil, 500 mg J9190 Office 17 22 $46
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 31 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $413
$413 — —
Bimzelx
  • UCB, Inc. $144
$144 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $139
$139 — —
OPZELURA
  • Incyte Corporation $117
$117 — —
TALTZ
  • Lilly USA, LLC $117
$117 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

369 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record